Silver Book Fact

After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who received traditional chemotherapy.

Aspinall, M and R Hamermesh. Realizing the Promise of Personalized Medicine. Harvard Bus Rev. 2007; 85(10): 108-17. https://hbr.org/2007/10/realizing-the-promise-of-personalized-medicine

Reference

Title
Realizing the Promise of Personalized Medicine
Publication
Harvard Bus Rev
Publication Date
2007
Authors
Aspinall, M and R Hamermesh
Volume & Issue
Volume 85, Issue 10
Pages
108-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Increased use of medical technology, like colonoscopy and sigmoidoscopy for colon cancer screening, could save $178.2 billion between 2010 and 2035.  
  • Gains in healthy years of life and social value from cancer R&D
     
  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.   
  • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.  
  • Widespread use of cancer vaccines could result in a cure of melanoma/renal cell carcinomas and a 25% boost in survival for all other cancers.